Wheelchair-using minister to join Bennett-Johnson meet after COP26 entry farce
Energy Minister Karine Elharrar, who has muscular dystrophy, was unable to enter environmental summit in Glasgow because venue was not accessible #summit #venue #karineelharrar #glasgow #cop26 #minister #bennettjohnson (Source: Reuters: Health)
Source: Reuters: Health - November 2, 2021 Category: Consumer Health News Source Type: news

AMRA joins clinical trial on muscular dystrophy
AMRA Medical will be involved in the Facioscapulohumeral Muscular Dystroph...Read more on AuntMinnie.comRelated Reading: AMRA touts clinical trial results AMRA adds UK Biobank images to database AMRA teams up with National University of Singapore AMRA highlights body composition analysis research AMRA wins FDA clearance for MR software (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - October 15, 2021 Category: Radiology Source Type: news

Data up to 8-years for Roche ’s OCREVUS (ocrelizumab) show early and ongoing treatment significantly reduced risk of requiring a walking aid in relapsing multiple sclerosis and disability progression in primary progressive multiple sclerosis
Basel, 13 October 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new long-term data that reinforce the benefit of early initiation and ongoing treatment of OCREVUS® (ocrelizumab) on disability progression in relapsing multiple sclerosis (RMS) and primary progressive MS (PPMS), as well as safety outcomes for an analysis of shorter 2-hour infusion in minority populations. OCREVUS data from all clinical trials consistently show a favourable benefit-risk profile over eight years. Roche and research partners will also present four late-breaking abstracts to share the latest data regarding COVID-19 and vaccine resp...
Source: Roche Media News - October 13, 2021 Category: Pharmaceuticals Source Type: news

Data up to 8-years for Roche ’s OCREVUS (ocrelizumab) show early and ongoing treatment significantly reduced risk of requiring a walking aid in relapsing multiple sclerosis and disability progression in primary progressive multiple sclerosis
Basel, 13 October 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new long-term data that reinforce the benefit of early initiation and ongoing treatment of OCREVUS® (ocrelizumab) on disability progression in relapsing multiple sclerosis (RMS) and primary progressive MS (PPMS), as well as safety outcomes for an analysis of shorter 2-hour infusion in minority populations. OCREVUS data from all clinical trials consistently show a favourable benefit-risk profile over eight years. Roche and research partners will also present four late-breaking abstracts to share the latest data regarding COVID-19 and vaccine resp...
Source: Roche Investor Update - October 13, 2021 Category: Pharmaceuticals Source Type: news

Roche presents new data at World Muscle Society (WMS) 2021 highlighting new advances for people living with rare neuromuscular disorders
Basel, 24 September 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced data from across its growing neuromuscular portfolio at the World Muscle Society (WMS) Virtual Congress 20 – 24 September 2021. The presentations included additional results from the RAINBOWFISH study, evaluating the efficacy and safety of Evrysdi® (risdiplam) in babies with pre-symptomatic spinal muscular atrophy (SMA) from birth to six weeks of age and data supporting the continued clinical investig ation of gene therapy, SRP-9001, in Duchenne muscular dystrophy (DMD).“These new data for Evrysdi may help extend the potential benefits of th...
Source: Roche Investor Update - September 24, 2021 Category: Pharmaceuticals Source Type: news

Roche presents new data at World Muscle Society (WMS) 2021 highlighting new advances for people living with rare neuromuscular disorders
Basel, 24 September 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced data from across its growing neuromuscular portfolio at the World Muscle Society (WMS) Virtual Congress 20 – 24 September 2021. The presentations included additional results from the RAINBOWFISH study, evaluating the efficacy and safety of Evrysdi® (risdiplam) in babies with pre-symptomatic spinal muscular atrophy (SMA) from birth to six weeks of age and data supporting the continued clinical investig ation of gene therapy, SRP-9001, in Duchenne muscular dystrophy (DMD).“These new data for Evrysdi may help extend the potential benefits of th...
Source: Roche Media News - September 24, 2021 Category: Pharmaceuticals Source Type: news

At What Age Is Muscular Dystrophy Diagnosed
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - September 7, 2021 Category: General Medicine Source Type: news

Screening for Duchenne Muscular Dystrophy Now Available for All Babies Born at the Brigham
The Brigham is the first birth hospital in the nation to develop a program that offers parents an option to have their newborn screened for Duchenne; through early diagnosis, screening may help families take advantage of therapeutic interventions (Source: BWH News)
Source: BWH News - July 22, 2021 Category: Hospital Management Source Type: news

A small molecule induces readthrough of cystic fibrosis CFTR nonsense mutations
(University of Alabama at Birmingham) An experimental drug reported in Nature Communications suggests that a " path is clearly achievable " to treat currently untreatable cases of cystic fibrosis disease caused by nonsense mutations. This includes about 11 percent of cystic fibrosis patients, as well as patients with other genetic diseases, including Duchenne muscular dystrophy,β-thalassemia and numerous types of cancers, that are also caused by nonsense mutations. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 19, 2021 Category: International Medicine & Public Health Source Type: news

Roche ’s ENSPRYNG approved by European Commission as first and only at-home subcutaneous treatment for neuromyelitis optica spectrum disorder (NMOSD)
Basel, 28 June 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission (EC) has approved ENSPRYNG ® (satralizumab) for the treatment of adults and adolescents from 12 years of age living with anti-aquaporin-4 antibody (AQP4-IgG) seropositive neuromyelitis optica spectrum disorder (NMOSD), as a monotherapy or in combination with immunosuppressive therapy (IST). ENSPRYNG is the first and only NMO SD treatment that is administered subcutaneously every four weeks, allowing home-dosing after appropriate training.“An NMOSD relapse can be devastating, causing permanent neurological damage and dis...
Source: Roche Investor Update - June 28, 2021 Category: Pharmaceuticals Source Type: news

Roche ’s ENSPRYNG approved by European Commission as first and only at-home subcutaneous treatment for neuromyelitis optica spectrum disorder (NMOSD)
Basel, 28 June 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission (EC) has approved ENSPRYNG ® (satralizumab) for the treatment of adults and adolescents from 12 years of age living with anti-aquaporin-4 antibody (AQP4-IgG) seropositive neuromyelitis optica spectrum disorder (NMOSD), as a monotherapy or in combination with immunosuppressive therapy (IST). ENSPRYNG is the first and only NMO SD treatment that is administered subcutaneously every four weeks, allowing home-dosing after appropriate training.“An NMOSD relapse can be devastating, causing permanent neurological damage and dis...
Source: Roche Media News - June 28, 2021 Category: Pharmaceuticals Source Type: news

What Are the Stages of Muscular Dystrophy?
Title: What Are the Stages of Muscular Dystrophy?Category: Diseases and ConditionsCreated: 6/17/2021 12:00:00 AMLast Editorial Review: 6/17/2021 12:00:00 AM (Source: MedicineNet Kids Health General)
Source: MedicineNet Kids Health General - June 17, 2021 Category: Pediatrics Source Type: news

A Space in Time review – lyrical portrait of a family facing an incurable disorder
This poignant documentary about two young brothers with Duchenne muscular dystrophy celebrates the power of love and togethernessHere is a deeply personal documentary that raises awareness about a disability without neglecting the interiority of those living with the condition. Co-directed by Riccardo Servini and Nick Taussig, the film follows the Taussig family ’s experience of Duchenne muscular dystrophy, a genetic disorder that affects their young sons, Theo and Oscar.Duchenne is incurable and fatal. By the time Theo and Oscar are in their teens, they will be using wheelchairs full time; their 20s will come with venti...
Source: Guardian Unlimited Science - May 10, 2021 Category: Science Authors: Phuong Le Tags: Film Documentary films Health Society Culture Genetics Science Children Parents and parenting Family Biology Life and style Source Type: news

Mother and son share rare muscle disorder, treated decades apart by same doctor
Twenty-four years ago, Bobbi Heinold, 17, was diagnosed with facioscapulohumeral muscular dystrophy, a genetic muscle condition characterized by weakness, especially in the face, shoulder blades and upper arms. Doctors told her it could affect her quality of life. Bobbi and her mom drove from their Indiana home to Mayo Clinic in Rochester, Minnesota, to learn [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - May 6, 2021 Category: Databases & Libraries Source Type: news

A milestone in muscular dystrophy therapy
(Max Delbr ü ck Center for Molecular Medicine in the Helmholtz Association) A new gene-editing technique can be used to correct mutations in muscle stem cells, paving the way for the first potential cell therapy for genetic muscle disorders. The ECRC team led by Professor Simone Spuler have published their findings in the journal JCI Insight. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 30, 2021 Category: International Medicine & Public Health Source Type: news